Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.
María Nieto-CidTeresa Garriga-BarautAna Mª Plaza-MartínMiguel Tortajada-GirbésJavier Torres-BorregoJaime Lozano-BlascoLaura Moreno-GalarragaMª Del Mar Folqué-GiménezMontserrat Bosque GarcíaMirella GaboliAlejandro Lopez-NeyraCristina Rivas JuesasMaría Araceli Caballero-RabascoAndrea Freixa-BenaventeLaura Valdesoiro-NavarreteInés de Mir-MessaEsther Ballester-AsensioMaría Penín-AntónRaquel Romero-GarcíaJuan Navarro-MorónAlfredo Valenzuela-SoriaMercedes Sánchez MateosJosé Batlles-GarridoVerónica Sanz SantiagoÁlvaro Gimeno-Díaz de AtauriAnselmo Andrés-MartínElena Campos-AlonsoDavid Gómez-PastranaElena Vázquez-RodríguezLuz Martínez-PardoGenoveva Del Río-CamachoÁngel Mazón RamosAntonio Nieto GarcíaPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2023)
The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.